Delisting Determination,The Nasdaq Stock Market, LLC,
July 31, 2007, Urigen Pharmaceuticals,Inc. FKA Valentis,
Inc. The Nasdaq Stock Market, LLC (the Exchange) has
determined to remove from listing the
common stock of Urigen Pharmaceuticals, Inc. FKA
Valentis, Inc. (the Company), effective at the
opening of business on August 10, 2007.
Based on a review of the information
provided by the Company, Nasdaq Staff determined that
the Company no longerqualified for listing on the
Exchange as it failed to comply with the following
Marketplace Rules: 4310(c)(02); 4310(c)(24) and because
it raised public interest concerns under Marketplace Rule
4300. The Company was notified of Staffs determinations
on January 8, 2007 and February 21, 2007. The Company
requested a review of the Staffs determination
before the Listing Qualifications Hearings Panel. Upon review
of the information provided by the Company, the Panel
determined that the Company did not qualify for inclusion on
the Exchange based on its failure to comply with
the following Marketplace Rules: 4310(c)(02), 4310(c)(04)
and 4300. The Company was notified of the Panels decision
on May 17, 2007 and trading in the Companys securities
was suspended on May 21, 2007. The Company did not
request a review of the Panels decision by the Nasdaq
Listing and Hearing Review Council and the Listing
Council did not call the matter for review. The Panels
Determination to delist the Company became final on
July 2, 2007.